CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib

J Clin Oncol. 2011 May 20;29(15):e443-5. doi: 10.1200/JCO.2010.34.1313. Epub 2011 Mar 21.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anaplastic Lymphoma Kinase
  • Carcinoma, Non-Small-Cell Lung / cerebrospinal fluid*
  • Crizotinib
  • Fatal Outcome
  • Humans
  • Lung Neoplasms / cerebrospinal fluid*
  • Male
  • Protein Kinase Inhibitors / cerebrospinal fluid*
  • Pyrazoles / cerebrospinal fluid*
  • Pyridines / cerebrospinal fluid*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases

Associated data

  • ClinicalTrials.gov/NCT00585195